"Designing Growth Strategies is in our DNA"

Generic Drugs Market Size, Share & Industry Analysis, By Drug class (Antipyretic, Antihistamines, Analgesics, Antibiotics, Antihypertensive, Antidiabetic, Others), By Indication (Cardiology, Diabetology, Pulmonology, Gastroenterology, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Regional Forecast 2022-2029

Region : Global | Report ID: FBI105815 | Status : Ongoing

 

KEY MARKET INSIGHTS

Generic drugs are non branded medications that are addressed by their active pharmaceutical ingredient. These drugs have the same pharmacologic effects as that intended of their branded versions and therefore are safe to use. Generic drugs are generally inexpensive as the manufacturers do not require to invest in development and marketing costs that are to be done for branded drugs. Since patents lapse every decade or so, companies are  incentivised to scale production and market their generic versions, which improves availability and affordability of generic. For instance, Humira is a patent with Abbvie. The expiry in 2016 have spiked generic copies such as Amjevita, Qletli, and Cyltezo. Recent developments in biologics and bio similar sector are also propelling the growth of global generic drugs market.


Moreover, new companies are entering into generic drugs production with an intention to gain significant market share. As a result, they are offering generic drugs with competitive pricing, thereby making generic even more affordable. For instance, Eylea and Stelara are specialty drugs which would be lapsing by 2025 to which companies have developed relevant biologics ready to launch in the segment. Growing prevalence of chronic diseases is expected to augment growth for generic drug market globally.


Some of the key drivers of generic drugs are prevalence of chronic diseases which has created a demand for affordable medication. Moreover, a lower price of generic drugs as compared to branded counterparts, is one of the key factors driving adoption of generic drugs in developing as well as developed economines. Moreover, the patent expiries of blockbuster drugs are influencing development of generic copies and anticipated to drive the market growth in near future. Also, new entrants in the generic drug and biosimilar drug market are offering cost effective and efficient generic versions of branded drugs which is also supporting the market growth.


Key Market Driver -

Growing prevalence of chronic diseases, Increasing patent expiries

Key Market Restraint -

Lack of awareness about generic drugs


Market Segmentation:


Globally, the generic drugs market can be segmented on the basis of drug class, indication, distribution channel and region. Based on the drug class, the market can be segmented into antipyretics, antihistamines, analgesics, antibiotics, antihypertensive, antidiabetic and others. Based on indication, the market can be segmented into cardiology, diabetology, pulmonology, gastroenterology and others. Based on distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies and online pharmacies. Geographically, the generic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.


Key Players Covered:


Some of the major companies that are present in the generic drugs market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Viatris Inc., Fresenius kabi AG, Aurobindo pharma, Lupin, Aspen holdings, Amneal Pharmaceuticals LLC., other prominent players.


Key Insights:



  • Key Industry Trends

  • Recent availability of lapsed patents and newly found indications of existing drugs.

  • Key Industry Developments Mergers, Acquisitions, And Collaborations


Regional Analysis:


Geographically, the generic drugs market is segmented into North America, Europe, Asia pacific, Latin America, and the Middle East & Africa. North America leads the generic drugs market. According to the Commonwealth Fund, in 2018, the U.S. spent 16.9 percent of gross domestic product (GDP) on health care, the second-highest ranking country, Switzerland, spent 12.2 percent of the gross domestic product (GDP) on health care. Europe anticipates growth in the global generic drugs market due to government initiatives and advancement in healthcare which will promote market share of Europe on a global scale. For instance, European Medicines Agency (EMA) promotes generic drug applications along with hybrids for companies to market their versions. This will encourage more companies to introduce generic versions of branded drugs in the region. Asia pacific anticipated growth in generic drugs market due to rising prevalence of chronic diseases and favorable government initiatives for generic medicines which will reflect positively on market growth. According to a study by the Centre of Disease Control and Prevention of U.S. Department of Health & Human Services, in September 2020, 51.8% of total US adult patients had at least 1 of 10 selected diagnosed chronic conditions (arthritis, cancer, chronic obstructive pulmonary disease, coronary heart disease, current asthma, diabetes, hepatitis, hypertension, stroke, and weak or failing kidneys), and 27.2% of US adult patients had multiple chronic conditions. Rising prevalence of such chronic ailments are subject to increase in treatment rates thereby increasing demand for the generic drugs market. Latin America is anticipated to show significant growth in the generic drugs market. Healthcare expenditure and need for sustainable healthcare are some factors that will affect growth positively. For instance, in March 2021, Biocon launched its generic drugs in Brazil in a partnership with Libbs Farmaceutica. This partnership will improve the market size and make these generic drugs accessible and affordable. Middle East & Africa are expected to showcase substantial growth due to rise in awareness and increase in healthcare expenditure during the forecast period.


To gain extensive insights into the market, Request for Customization


Segmentation


























 ATTRIBUTES 


 DETAILS     

By Drug class




  • Antipyretic

  • Antihistamines

  • Analgesics

  • Antibiotics

  • Antihypertensive

  • Antidiabetic

  • Others



By Indication




  • Cardiology

  • Diabetology



  • Pulmonology

  • Gastroenterology

  • Others



By Distribution channel




  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies



By Geography




  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)



Generic drugs Market Industry Developments



  • In June 2021, Teva Pharmaceutical Industries Ltd and Bioeq AG announced strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to Lucentis (ranibizumab) in Europe, Canada, Israel and New Zealand.

  • In November 2020, Pfizer and Mylan announced merger of Pfizer’s Upjohn generics unit with Mylan N.V. generic unit to form Viatris. Due to this merger Viatris will become one of the prominent players in the generic drugs industry.

  • In July 2021, Sandoz, a global leader in generic and biosimilar medicines launched generic version of Ferumoxytol, an intravenous medicine used to treat iron deficiency anaemia (IDA).


Generic Drugs Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2021
  • 2018-2020

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850
    Pre Book

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Amgen
Roche
uniliver
iqvia
Johnson

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X